SCHEMBL4714667

SCHEMBL4714667

Cc1cccc(Cn2c(C(N)=O)cc3c2ccc(=O)n3-c2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 4/20 0.47
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAPT P10636 2/20 0.44
THRB P10828 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
F10 P00742 3/20 0.43
ERCC5 P28715 1/20 0.42
FEN1 P39748 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TP53 P04637 2/20 0.41
ECE1 P42892 1/20 0.41
RGS4 P49798 1/20 0.41
RGS8 P57771 1/20 0.41
CCR2 P41597 1/20 0.40
BRD4 O60885 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4711636 0.91 MEN1 (0.47) ALDH1A1MEN1KMT2AL3MBTL1MAPT
SCHEMBL4715213 0.87 CCR2 (0.51) PLA2G10ALDH1A1KMT2AL3MBTL1MAPT
SCHEMBL4789434 0.86 ALDH1A1 (0.53) ALDH1A1MEN1KMT2AL3MBTL1MAPT
SCHEMBL4714198 0.85 ALDH1A1 (0.45) ALDH1A1MEN1KMT2AL3MBTL1MAPT
SCHEMBL4715856 0.84 CCR2 (0.40) PLA2G10ALDH1A1KDM4EF10CCR2
SCHEMBL4715522 0.84 RGS4 (0.48) L3MBTL1MAPTKDM4EHPGDF10
SCHEMBL4712363 0.80 CCR2 (0.50) PLA2G10CCR2
SCHEMBL4717315 0.79 SPHK2 (0.42) ALDH1A1MEN1KMT2AL3MBTL1MAPT
SCHEMBL4716102 0.78 MAPT (0.57) ALDH1A1MEN1KMT2AL3MBTL1MAPT
SCHEMBL5119050 0.78 CCR2 (0.62) MAPTERCC5CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US claimed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US claimed
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 PLA2G10 4695/4885ALDH1A1 3407/4885MEN1 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.